The results showed: no appreciable detrimental effect on quality of life for patients receiving maintenance treatment with Lynparza versus patients on placebo, thereby meeting the QoL primary endpoint ...

QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced that it will no longer sponsor the 13C-sucrose breath test program, which was previously offered free of ...

Purpose: This review evaluates how theory-driven models of health-related quality of life (QoL) take into account the methodological and conceptual problems besetting the field. Methodology: 68 models ...